Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Revvity

Tracked across 2 events · 12 articles · First seen Jun 26, 2026 · Last active Sep 20, 2026

Sentiment
35
Attention
4
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
2 10
Business
Revvity, Inc. (NYSE: RVTY) announced on September 9, 2026 that it has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specializing in human cell models and preclinical research…
Impact: Revvity is the acquirer, expanding its Life Sciences portfolio with HCD's human pancreatic beta cell models and preclinical research capabilities. The deal is expected to close in Q4 2026 subject to regulatory approvals, and its stock reportedly fell 2.3% since the announcement.
Sep 09, 2026 · 6 articles
4 60
Tech
Impact: Revvity is listed among the top companies in the epigenetics market, indicating its participation in the industry.
Jun 26, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Revvity live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.